Clinical trials: Affective Disorder
Depression, Major Depressive Disorder
Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)
Transcranial Light Therapy involves non-invasive and invisible beams of light that increase energy metabolism in the brain. Transcranial light therapy has been found to promote brain metabolism which may help people with…
- Trial name
- ELATED-3 (NCT02959307)
- Testing
- Transcranial Light Therapy
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Brexpiprazole for Bipolar Depression
The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state.
- Trial name
- NCT03427892
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder, Major
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.
- Trial name
- NCT01389752
- Testing
- LY2216684, Activated Charcoal
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of Patients With Major Depressive Disorder and Residual Apathy
The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a…
- Trial name
- NCT00985504
- Testing
- Duloxetine, Escitalopram
- Where
- 15 sites in Australia, Canada and 3 more
- Volunteers
- 483 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01157078
- Testing
- TC-5214
- Where
- 51 sites in United States, India
- Volunteers
- 319 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Depression
Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression
This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.
- Trial name
- NCT00468676
- Testing
- Nurse-led case management, Treatment as usual
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Washington
Depression
Buprenorphine for Late-Life Treatment Resistant Depression
The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.
- Trial name
- BUILD (NCT01071538)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder (MDD)
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding…
- Trial name
- NCT02012218
- Testing
- ADT, Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 61 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with…
- Trial name
- NCT02191397
- Testing
- Bupropion, Escitalopram
- Where
- 20 sites in China
- Volunteers
- 534 people
- Sponsor
- GlaxoSmithKline
Major Depression, Epilepsy
Lexapro for Major Depression in Patients With Epilepsy
The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms…
- Trial name
- NCT01244724
- Testing
- Lexapro
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD.
- Trial name
- B2411003 (NCT00770289)
- Testing
- Cohort
- Where
- 3 sites in Greece
- Volunteers
- 851 people
- Sponsor
- Pfizer
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
Feasibility Electrical Stimulation Study for Visual Hallucinations
The visual system has increasingly been recognized as an important site of injury in patients with schizophrenia and other psychoses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT04870710
- Testing
- transcranial electrical stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
This 26-week open-label extension study is designed to provide information on the safety and tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term administration in children and adolescents…
- Trial name
- NCT03768726
- Testing
- Ziprasidone
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients.
- Trial name
- NCT02229825
- Testing
- Duloxetine
- Volunteers
- 339 people
- Sponsor
- Boehringer Ingelheim
Bipolar Disorder, Alcoholism
Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder
The purpose of this study is determine whether the use of topiramate is effective in the treatment of alcohol dependence (i.e. decreases drinking) in patients with bipolar disorder.
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Dependence
- Trial name
- NCT00572117
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.